Elizabeth Beierle

Dr. Elizabeth Beierle

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
RSRobert Skinner
Robert Skinner
ATAngelica Trujillo
Angelica Trujillo
XMXiaojie Ma
Xiaojie Ma
EBElizabeth Beierle
Elizabeth Beierle

1 April 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
EBElizabeth Beierle
Elizabeth Beierle
ATAngelica Trujillo
Angelica Trujillo
ANAbhilasha Nagaram
Abhilasha Nagaram
EKElena V. Kurenova
Elena V. Kurenova
RFRichard Finch
Richard Finch
VGVita M. Golubovskaya
Vita M. Golubovskaya
N-MYC is a transcription factor that plays an important role in cellular survival in neuroblastoma, and amplification of the N-MYC oncogene is the primary adverse prognostic indicator for neuroblastoma. Focal adhesion kinase (FAK) is a survival factor that has been shown to be overexpressed in many types of human cancers. In this study, we investigated the role of N-MYC regulation of FAK expression in neuroblastoma. We first found a correlation between N-MYC and FAK expression in neuroblastoma. Real time quantitative PCR demonstrated an increase in FAK mRNA abundance in the N-MYC-amplified IMR-32 compared with the nonamplified SK-N-AS neuroblastoma cell lines. FAK protein expression also correlated positively with N-MYC expression in the N-MYC-amplified IMR-32 versus nonamplified SK-N-AS neuroblastoma cell lines. The same results were seen with the isogenic N-MYC+ (Tet–) and N-MYC– (Tet+) neuroblastoma cell lines. Promoter-reporter assays showed that activity of the FAK promoter was increased in the N-MYC-amplified IMR-32 cell line, in the N-MYC-transfected SK-N-AS nonamplified cell line, and in the isogenic N-MYC+ (Tet–) neuroblastoma cell lines compared with the nonamplified and N-MYC-nonexpressing cell lines. We also identified two N-MYC binding sites in the FAK promoter sequence and showed binding of N-MYC transcription factor to the FAK promoter through electrophoretic mobility shift, chromatin immunoprecipitation, and dual luciferase assays. Finally down-regulation of FAK expression in N-MYC-inducible neuroblastoma cell lines with FAK small interfering RNA or a dominant-negative FAK inhibitor (AdFAK-CD) significantly decreased viability and increased apoptosis in the N-MYC+ (Tet–) cells compared with the isogenic N-MYC– (Tet+) cells, demonstrating the biological significance of FAK overexpression in the N-MYC-expressing cell lines. This is the first report linking N-MYC and FAK in neuroblastoma, and it clearly demonstrates that N-MYC induces FAK expression. The results indicate that N-MYC regulation of FAK expression can control cellular functions in isogenic N-MYC–/+ (Tet+/–) neuroblastoma cell lines.

1 August 2005 in Seminars in Pediatric Surgery
Verified
Journal Article
Closed access
JNJosef Neu
Josef Neu
MCMike Chen
Mike Chen
EBElizabeth Beierle
Elizabeth Beierle

1 November 2015 in Journal of Surgical Research
Verified
Journal Article
Closed access
AWAlicia M. Waters
Alicia M. Waters
DTDaniel H. Teitelbaum
Daniel H. Teitelbaum
VTVivian Thorne
Vivian Thorne
ABAthos Bousvaros
Athos Bousvaros
RNR. Adam Noel
R. Adam Noel
EBElizabeth Beierle
Elizabeth Beierle

1 March 2010 in Cell Cycle
Verified
Journal Article
Closed access
EBElizabeth Beierle
Elizabeth Beierle
XMXiaojie Ma
Xiaojie Ma
JSJerry Stewart
Jerry Stewart
CNCarl Nyberg
Carl Nyberg
ATAngelica Trujillo
Angelica Trujillo
VGVita Golubovskaya
Vita Golubovskaya
Neuroblastoma is the most common extracranial solid tumor of childhood. Focal adhesion kinase (FAK) is an intracellular kinase that regulates both cellular adhesion and apoptosis. FAK is overexpressed in a number of human tumors including neuroblastoma. Previously, we have shown that the MYCN oncogene, the primary adverse prognostic indicator in neuroblastoma, regulates the expression of FAK in neuroblastoma. In this study, we have examined the effects of FAK inhibition upon neuroblastoma using a small molecule [1,2,4,5-benzenetetraamine tetrahydrochloride (Y15)] to inhibit FAK expression and the phosphorylation of FAK at the Y397 site. Utilizing both non-isogenic and isogenic MYCN+/MYCN- neuroblastoma cell lines, we found that Y15 effectively diminished phosphorylation of the Y397 site of FAK. Treatment with Y15 resulted in increased detachment, decreased cell viability and increased apoptosis in the neuroblastoma cell lines. We also found that the cell lines with higher MYCN are more sensitive to Y15 tr...

8 November 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
SGSajia GC
Sajia GC
KTKaysaw Tuy
Kaysaw Tuy
LRLucas Rickenbacker
Lucas Rickenbacker
RJRobert Jones
Robert Jones
ACAsmi Chakraborty
Asmi Chakraborty
AHAnita Hjelmeland
Anita Hjelmeland
One of the least-investigated areas of brain pathology research is glycosylation, which is a critical regulator of cell surface protein structure and function. β-Galactoside α2,6-sialyltransferase ( ST6GAL1 ) is the primary enzyme that α2,6 sialylates N-glycosylated proteins destined for the plasma membrane or secretion, thereby modulating cell signaling and behavior. We demonstrate a potentially novel, protumorigenic role for α2,6 sialylation and ST6GAL1 in the deadly brain tumor glioblastoma (GBM). GBM cells with high α2,6 sialylation exhibited increased in vitro growth and self-renewal capacity and decreased mouse survival when orthotopically injected. α2,6 Sialylation was regulated by ST6GAL1 in GBM, and ST6GAL1 was elevated in brain tumor-initiating cells (BTICs). Knockdown of ST6GAL1 in BTICs decreased in vitro growth, self-renewal capacity, and tumorigenic potential. ST6GAL1 regulates levels of the known BTIC regulators PDGF Receptor β ( PDGFRB ), Activated Leukocyte Cell Adhesion Molecule, and Neuropilin, which were confirmed to bind to a lectin-recognizing α2,6 sialic acid. Loss of ST6GAL1 was confirmed to decrease PDGFRB α2,6 sialylation, total protein levels, and the induction of phosphorylation by PDGF-BB. Thus, ST6GAL1 -mediated α2,6 sialylation of a select subset of cell surface receptors, including PDGFRB , increases GBM growth.